Middle fossa decompression for hearing preservation: A review of institutional results and indications

Otology and Neurotology

Volumn 32, Issue 6, 2011, Pages 1017-1024

  Slattery, William H ^a   Hoa, Michael ^a   Bonne, Nicolas ^a   Friedman, Rick A ^a   Schwartz, Marc S ^a   Fisher, Laurel M ^a   Brackmann, Derald E ^a  

^a HOUSE RESEARCH INSTITUTE   (United States)

Author keywords

Hearing preservation; Internal auditory canal; Middle fossa decompression; Neurofibromatosis type 2; Only hearing ear; Quality of life; Vestibular schwannoma

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUDITORY THRESHOLD; CHILD; DECOMPRESSION SURGERY; FEMALE; HEARING LOSS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MIDDLE CRANIAL FOSSA; NEUROFIBROMATOSIS; NEUROMA; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CHILD; CRANIAL FOSSA, MIDDLE; DECOMPRESSION, SURGICAL; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051707037     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e3182267eb7     Document Type: Review

References (24)

1. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet Part A 2010;152A: 327-32.
2. Evans DG. Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
3. Miyamoto RT, Roos KL, Campbell RL, Worth RM. Contemporary management of neurofibromatosis. Ann Otol Rhinol Laryngol 1991;100:38-43.
4. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates. Neurosurg 2007;60:460-70.
5. Balasubramamiam A, Shannon P, Hodaie M, et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: Case report and review of the literature. Neuro Oncol 2007;9:447-53.
6. Briggs RJ, Brackmann DE, Baser ME, Hitselberger WE. Comprehensive management of bilateral acoustic neuromas: Current perspectives. Arch Otolaryngol Head Neck Surg 1994;120:1307-14. (Pubitemid 24378570)
7. Gadre AK, Kwartler JA, Brackmann DE, House WF, Hitselberger WE. Middle fossa decompression of the internal auditory canal in acoustic neuroma surgery: A therapeutic alternative. Laryngoscope 1990;100:948-52. (Pubitemid 20301593)
8. Slattery WH, Brackmann DE, Hitselberger WE. Middle fossa approach for hearing preservation with acoustic neuromas. Am J Otol 1997;18:596-601. (Pubitemid 27428347)
9. Slattery WH, Brackmann DE, Hitselberger WE. Hearing preservation in neurofibromatosis type 2. Am J Otol 1998;19:638-43. (Pubitemid 28409420)
10. Shelton C, Hitselberger WE. Treatment of small acoustic tumors: Now or later? Laryngoscope 1991;101:925-8.
11. Brackmann DE, Fayad JN, Slattery WH, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 2001;49:274-83. (Pubitemid 32721055)
12. Friedman RA, Kesser B, Brackmann DE, Fisher LM, Slattery WH, Hitselberger WE. Long-term hearing preservation after middle fossa removal of vestibular schwannoma. Otolaryngol Head Neck Surg 2003;129:660-5. (Pubitemid 37509764)
13. Shelton C, Brackmann DE, House WF. Middle fossa approach. In: Brackmann DE, Shelton C, Arriaga MA, eds. Otologic Surgery, 3rd ed. Philadelphia, PA: Elsevier, 2010:581-9.
14. Carhart R, Jerger JF. Preferred method for clinical determination of pure-tone thresholds. J Speech Hearing Dis 1959;24:330-45.
15. Dobie RA. Reliability and validity of industrial audiometry: Implications for hearing conservation program design. Laryngoscope 1983;93:906-27. (Pubitemid 13067854)
16. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18. (Pubitemid 9028176)
17. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of OtolaryngologyYHead and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113: 179-80.
18. Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DGR. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 2010;35:291-9.
19. Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope 2000;110:497-508. (Pubitemid 30198702)
20. Lalwani AK, Abaza MM, Makariou EV, Armstrong M. Audiologic presentation of vestibular schwannomas in neurofibromatosis type 2. Am J Otol 1998;19:352-7.
21. Fisher LM, Doherty JK, Lev MH, Slattery WH. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: Neurofibromatosis natural history consortium. Otol Neurotol 2009;30:835-41.
22. Stankovic KM, Mrugala MM, Martuza RL, et al. Genetic determinants of hearing loss associated with vestibular schwannomas. Otol Neurotol 2009;30:661-7.
23. Linthicum FH Jr., Brackmann DE. Bilateral acoustic tumors. A diagnostic and surgical challenge. Arch Otolaryngol 1980;106: 729-33. (Pubitemid 11194181)
24. Linthicum FH Jr. Unusual audiometric and histologic findings in bilateral acoustic neurinomas. Ann Otol Rhinol Laryngol 1972;81: 433-7.